Salspera

Immuno-oncology biotech Salspera files for a US IPO IPO Overview Salspera, a clinical-stage cancer biotech developing live biopharmaceuticals to stimulate an immune response, filed on Monday with the SEC for an initial public offering. The company filed with an $85... Read more